Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZN AstraZeneca	$73.05 -1.4%	$73.00	$62.75 ▼ $87.68	$226.54B	0.41	4.94 million shs	6.08 million shs
AZN AstraZeneca	$73.05 -1.4%	$73.00	$62.75 ▼ $87.68	$226.54B	0.41	4.94 million shs	6.08 million shs
AZNCF AstraZeneca	$147.55 +2.9%	$145.60	$120.64 ▼ $175.00	N/A	N/A	2,126 shs	716 shs
GSK GSK	$38.65 +0.2%	$36.77	$31.72 ▼ $45.93	$80.00B	0.58	4.34 million shs	5.84 million shs
GSK GSK	$38.65 +0.2%	$36.77	$31.72 ▼ $45.93	$80.00B	0.58	4.34 million shs	5.84 million shs
LLY Eli Lilly and Company	$852.35 -1.5%	$837.36	$711.40 ▼ $972.53	$808.17B	0.34	3.15 million shs	2.66 million shs
ON Onsemi	$45.31 -0.8%	$49.79	$41.59 ▼ $80.08	$19.09B	1.59	6.85 million shs	4.76 million shs
PFE Pfizer	$25.56 -2.2%	$26.15	$24.48 ▼ $31.54	$144.96B	0.61	36.65 million shs	47.47 million shs
SDGR Schrödinger	$21.45 -5.7%	$22.98	$16.67 ▼ $29.15	$1.57B	1.62	745,702 shs	848,483 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZN AstraZeneca	-1.12%	-4.24%	-0.15%	+11.75%	+11.82%
AZN AstraZeneca	-1.12%	-4.24%	-0.15%	+11.75%	+11.82%
AZNCF AstraZeneca	-6.52%	-7.46%	+0.71%	+9.38%	+8.34%
GSK GSK	-1.63%	-4.27%	+5.35%	+13.38%	-8.89%
GSK GSK	-1.63%	-4.27%	+5.35%	+13.38%	-8.89%
LLY Eli Lilly and Company	+3.16%	+4.90%	-0.94%	+8.83%	+12.37%
ON Onsemi	+4.34%	+3.70%	-15.49%	-32.72%	-38.83%
PFE Pfizer	-0.27%	+0.26%	-0.70%	-2.27%	-4.48%
SDGR Schrödinger	+4.36%	-4.13%	+0.49%	+15.31%	-15.02%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AZN AstraZeneca	2.2714 of 5 stars	2.6	3.0	1.7	0.0	2.9	0.0	1.3
AZN AstraZeneca	2.2714 of 5 stars	2.6	3.0	1.7	0.0	2.9	0.0	1.3
AZNCF AstraZeneca	0.1517 of 5 stars	0.0	0.0	1.7	0.0	1.7	0.8	0.0
GSK GSK	2.5152 of 5 stars	2.3	3.0	2.5	0.0	2.4	0.0	1.9
GSK GSK	2.5152 of 5 stars	2.3	3.0	2.5	0.0	2.4	0.0	1.9
LLY Eli Lilly and Company	4.6221 of 5 stars	2.4	3.0	3.3	4.0	2.9	2.5	1.9
ON Onsemi	4.7933 of 5 stars	4.3	2.0	0.0	3.2	2.7	1.7	3.1
PFE Pfizer	4.9844 of 5 stars	3.3	3.0	4.2	4.2	2.8	3.3	3.1
SDGR Schrödinger	2.5614 of 5 stars	3.5	2.0	0.0	0.0	2.5	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZN AstraZeneca	3.10	Buy	$89.75	22.86% Upside
AZN AstraZeneca	3.10	Buy	$89.75	22.86% Upside
AZNCF AstraZeneca	0.00	N/A	N/A	N/A
GSK GSK	2.60	Moderate Buy	$43.25	11.90% Upside
GSK GSK	2.60	Moderate Buy	$43.25	11.90% Upside
LLY Eli Lilly and Company	2.85	Moderate Buy	$1,009.72	18.46% Upside
ON Onsemi	2.52	Moderate Buy	$66.50	46.77% Upside
PFE Pfizer	2.63	Moderate Buy	$31.92	24.89% Upside
SDGR Schrödinger	3.00	Buy	$32.29	50.52% Upside

Current Analyst Ratings Breakdown

Latest SDGR, AZN, AZN, AZNCF, LLY, GSK, GSK, ON, and PFE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/24/2025	ON Onsemi	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$71.00 ➝ $62.00
3/18/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/12/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/10/2025	PFE Pfizer	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/7/2025	ON Onsemi	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$60.00
3/6/2025	LLY Eli Lilly and Company	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$1,146.00
3/5/2025	LLY Eli Lilly and Company	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$970.00 ➝ $1,100.00
3/3/2025	ON Onsemi	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$57.00 ➝ $57.00
2/27/2025	ON Onsemi	Rosenblatt Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$49.00 ➝ $49.00
2/27/2025	SDGR Schrödinger	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $45.00
2/13/2025	AZN AstraZeneca	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy

(Data available from 3/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZN AstraZeneca	$54.07B	4.19	$6.20 per share	11.79	$13.18 per share	5.54
AZN AstraZeneca	$54.07B	4.19	$6.20 per share	11.79	$13.18 per share	5.54
AZNCF AstraZeneca	N/A	N/A	N/A	N/A	N/A	N/A
GSK GSK	$31.38B	2.55	$6.12 per share	6.32	$8.07 per share	4.79
GSK GSK	$31.38B	2.55	$6.12 per share	6.32	$8.07 per share	4.79
LLY Eli Lilly and Company	$45.04B	17.94	$13.90 per share	61.34	$15.05 per share	56.63
ON Onsemi	$7.08B	2.70	$4.50 per share	10.06	$20.92 per share	2.17
PFE Pfizer	$63.63B	2.28	$4.01 per share	6.38	$15.81 per share	1.62
SDGR Schrödinger	$207.54M	7.55	$0.57 per share	37.42	$7.60 per share	2.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZN AstraZeneca	$7.04B	$2.26	32.32	14.61	1.42	13.01%	32.23%	12.31%	4/24/2025 (Estimated)
AZN AstraZeneca	$7.04B	$2.26	32.32	14.61	1.42	13.01%	32.23%	12.31%	4/24/2025 (Estimated)
AZNCF AstraZeneca	N/A	$0.82	180.82	∞	N/A	N/A	N/A	N/A	4/29/2025 (Estimated)
GSK GSK	$3.29B	$1.59	24.31	8.31	1.12	8.13%	48.59%	11.11%	5/7/2025 (Estimated)
GSK GSK	$3.29B	$1.59	24.31	8.31	1.12	8.13%	48.59%	11.11%	5/7/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$11.71	72.79	27.39	1.40	23.51%	85.24%	16.19%	4/29/2025 (Estimated)
ON Onsemi	$1.57B	$3.63	12.48	12.31	16.74	22.21%	20.10%	12.36%	5/5/2025 (Estimated)
PFE Pfizer	$8.03B	$1.41	18.13	8.44	0.64	12.62%	19.47%	8.09%	4/29/2025 (Estimated)
SDGR Schrödinger	$40.72M	-$2.57	N/A	N/A	N/A	-91.84%	-35.77%	-24.51%	4/29/2025 (Estimated)

Latest SDGR, AZN, AZN, AZNCF, LLY, GSK, GSK, ON, and PFE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
2/26/2025	Q4 2024	SDGR Schrödinger	-$0.35	-$0.55	-$0.20	-$0.55	$83.20 million	$88.32 million
2/10/2025	Q4 2024	ON Onsemi	$0.98	$0.95	-$0.03	$0.88	$1.76 billion	N/A
2/6/2025	Q4 2024	AZN AstraZeneca	$1.10	$1.05	-$0.05	$0.48	$14.19 billion	N/A
2/6/2025	Q4 2024	AZN AstraZeneca	$1.10	$1.05	-$0.05	$0.48	$14.19 billion	N/A
2/6/2025	Q4 2024	LLY Eli Lilly and Company	$5.45	$5.32	-$0.13	$4.88	$13.42 billion	N/A
2/5/2025	Q4 2024	GSK GSK	$0.44	$0.59	+$0.15	$0.26	$7.75 billion	N/A
2/5/2025	Q4 2024	GSK GSK	$0.44	$0.59	+$0.15	$0.26	$7.75 billion	N/A
2/4/2025	Q4 2024	PFE Pfizer	$0.48	$0.63	+$0.15	$0.07	$17.26 billion	$17.76 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZN AstraZeneca	$2.06	2.82%	+1.98%	91.15%	N/A
AZN AstraZeneca	$2.06	2.82%	+1.98%	91.15%	N/A
AZNCF AstraZeneca	$2.80	1.90%	N/A	343.14%	N/A
GSK GSK	$1.57	4.06%	-17.33%	98.74%	N/A
GSK GSK	$1.57	4.06%	-17.33%	98.74%	N/A
LLY Eli Lilly and Company	$6.00	0.70%	+15.21%	51.24%	11 Years
ON Onsemi	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	6.73%	+2.50%	121.99%	16 Years
SDGR Schrödinger	N/A	N/A	N/A	N/A	N/A

Latest SDGR, AZN, AZN, AZNCF, LLY, GSK, GSK, ON, and PFE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/5/2025	GSK GSK	quarterly	$0.3932	4.2%	2/21/2025	2/21/2025	4/10/2025
2/5/2025	GSK GSK	quarterly	$0.3932	4.2%	2/21/2025	2/21/2025	4/10/2025
2/6/2025	AZN AstraZeneca	semi-annual	$1.03	2%	2/21/2025	2/21/2025	3/24/2025
2/6/2025	AZN AstraZeneca	semi-annual	$1.03	2%	2/21/2025	2/21/2025	3/24/2025
2/6/2025	AZNCF AstraZeneca		$2.10		2/19/2025	2/21/2025	3/24/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AZN AstraZeneca	0.65	0.93	0.74
AZN AstraZeneca	0.65	0.93	0.74
AZNCF AstraZeneca	N/A	N/A	N/A
GSK GSK	1.12	0.78	0.52
GSK GSK	1.12	0.78	0.52
LLY Eli Lilly and Company	2.00	1.15	0.97
ON Onsemi	0.38	5.06	3.38
PFE Pfizer	0.63	1.00	0.73
SDGR Schrödinger	N/A	4.11	4.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AZN AstraZeneca	20.35%
AZN AstraZeneca	20.35%
AZNCF AstraZeneca	40.87%
GSK GSK	15.74%
GSK GSK	15.74%
LLY Eli Lilly and Company	82.53%
ON Onsemi	97.70%
PFE Pfizer	68.36%
SDGR Schrödinger	79.05%

Insider Ownership

Company	Insider Ownership
AZN AstraZeneca	N/A
AZN AstraZeneca	N/A
AZNCF AstraZeneca	N/A
GSK GSK	10.00%
GSK GSK	10.00%
LLY Eli Lilly and Company	0.13%
ON Onsemi	0.31%
PFE Pfizer	0.06%
SDGR Schrödinger	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AZN AstraZeneca	83,500	3.10 billion	N/A	Optionable
AZN AstraZeneca	83,500	3.10 billion	N/A	Optionable
AZNCF AstraZeneca	83,500	N/A	N/A	Not Optionable
GSK GSK	90,100	2.07 billion	1.87 billion	Optionable
GSK GSK	90,100	2.07 billion	1.87 billion	Optionable
LLY Eli Lilly and Company	39,000	948.17 million	948.08 million	Optionable
ON Onsemi	26,490	421.42 million	420.12 million	Optionable
PFE Pfizer	83,000	5.67 billion	5.66 billion	Optionable
SDGR Schrödinger	790	73.04 million	66.59 million	Optionable

SDGR, AZN, AZN, AZNCF, LLY, GSK, GSK, ON, and PFE Headlines

Recent News About These Companies

Schrödinger, Inc. (NASDAQ:SDGR) Position Boosted by Amundi

March 21, 2025 | marketbeat.com

Schrödinger (NASDAQ:SDGR) Shares Down 5.4% - What's Next?

March 19, 2025 | marketbeat.com

Tejara Capital Ltd Trims Stake in Schrödinger, Inc. (NASDAQ:SDGR)

March 19, 2025 | marketbeat.com

Nikko Asset Management Americas Inc. Boosts Stock Position in Schrödinger, Inc. (NASDAQ:SDGR)

March 18, 2025 | marketbeat.com

Bank of New York Mellon Corp Sells 27,211 Shares of Schrödinger, Inc. (NASDAQ:SDGR)

March 16, 2025 | marketbeat.com

80,000 Shares in Schrödinger, Inc. (NASDAQ:SDGR) Acquired by Monaco Asset Management SAM

March 15, 2025 | marketbeat.com

Schrödinger (NASDAQ:SDGR) Trading Up 11.3% - Should You Buy?

March 12, 2025 | marketbeat.com

Schrödinger beruft Bridget van Kralingen in den Vorstand

March 10, 2025 | de.investing.com

Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen

March 10, 2025 | finance.yahoo.com

SchrÃ¶dinger Expands Board of Directors with Appointment of Bridget van Kralingen

March 10, 2025 | businesswire.com

Insider Selling: Schrödinger, Inc. (NASDAQ:SDGR) CFO Sells 5,491 Shares of Stock

March 5, 2025 | marketbeat.com

Leerink Partnrs Estimates Schrödinger FY2029 Earnings

March 3, 2025 | marketbeat.com

Schrödinger, Inc. (NASDAQ:SDGR) Receives Average Recommendation of "Buy" from Brokerages

March 2, 2025 | marketbeat.com

SchrÃ¶dinger: Still Waiting On A Catalyst

March 2, 2025 | seekingalpha.com

Schrödinger, Inc. (SDGR) Q4 2024 Earnings Call Transcript

March 1, 2025 | seekingalpha.com

Schrödinger, Inc. (SDGR) Q4 2024 Earnings Call Transcript

March 1, 2025 | seekingalpha.com

Schrödinger (NASDAQ:SDGR) Trading Up 7.7% - Here's What Happened

February 28, 2025 | marketbeat.com

Piper Sandler Lowers Schrödinger (NASDAQ:SDGR) Price Target to $45.00

February 28, 2025 | marketbeat.com

Schrodinger price target lowered to $45 from $50 at Piper Sandler

February 27, 2025 | markets.businessinsider.com

Schrödinger (NASDAQ:SDGR) Releases Quarterly Earnings Results, Misses Estimates By $0.20 EPS

February 27, 2025 | marketbeat.com

Schrödinger (NASDAQ:SDGR) Announces Quarterly Earnings Results

February 27, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Price Targets on NVIDIA Rise in Front of Earnings
By Sarah Horvath | February 24, 2025
View Price Targets on NVIDIA Rise in Front of Earnings
Warren Buffett Swaps VOO for This Reliable Dividend Stock
By Sarah Horvath | March 7, 2025
View Warren Buffett Swaps VOO for This Reliable Dividend Stock
NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
By Thomas Hughes | March 12, 2025
View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
Archer Aviation Stock Skids: Mistaking Progress for Bad News?
By Chris Markoch | February 24, 2025
View Archer Aviation Stock Skids: Mistaking Progress for Bad News?
AST SpaceMobile Stock Surges 17% After Analyst Upgrade
By Nathan Reiff | February 26, 2025
View AST SpaceMobile Stock Surges 17% After Analyst Upgrade

SDGR, AZN, AZN, AZNCF, LLY, GSK, GSK, ON, and PFE Company Descriptions

AstraZeneca NASDAQ:AZN

$73.05 -1.04 (-1.40%)

Closing price 04:00 PM Eastern

Extended Trading

$72.58 -0.47 (-0.64%)

As of 05:45 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca NASDAQ:AZN

$73.05 -1.04 (-1.40%)

Closing price 04:00 PM Eastern

Extended Trading

$72.58 -0.47 (-0.64%)

As of 05:45 PM Eastern

AstraZeneca OTCMKTS:AZNCF

$147.55 +4.14 (+2.88%)

As of 11:30 AM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

GSK NYSE:GSK

$38.65 +0.08 (+0.21%)

Closing price 03:58 PM Eastern

Extended Trading

$38.60 -0.05 (-0.14%)

As of 05:43 PM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

GSK NYSE:GSK

$38.65 +0.08 (+0.21%)

Closing price 03:58 PM Eastern

Extended Trading

$38.60 -0.05 (-0.14%)

As of 05:43 PM Eastern

Eli Lilly and Company NYSE:LLY

$852.35 -12.55 (-1.45%)

Closing price 03:58 PM Eastern

Extended Trading

$853.66 +1.31 (+0.15%)

As of 05:44 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Onsemi NASDAQ:ON

$45.31 -0.37 (-0.81%)

Closing price 04:00 PM Eastern

Extended Trading

$45.34 +0.03 (+0.08%)

As of 05:43 PM Eastern

onsemi is engaged in disruptive innovations and also a supplier of power and analog semiconductors. The firm offers vehicle electrification and safety, sustainable energy grids, industrial automation, and 5G and cloud infrastructure, with a focus on automotive and industrial end-markets. It operates through the following segments: Power Solutions Group, Advanced Solutions Group, and Intelligent Sensing Group. The Power Solutions Group segment offers discrete, module, and semiconductor products that perform multiple application functions, including power switching, power conversion, signal conditioning, circuit protection, signal amplification, and voltage reference functions. The Advanced Solutions Group segment is involved in the designing and developing of analog, mixed-signal, advanced logic, ASSPs and ASICs, Wi-Fi and power solutions for a broad base of end-users in the automotive, consumer, computing, industrial, communications, medical and aerospace/defense markets. The Intelligent Sensing Group segment is focused on the designing and developing of CMOS and CCD image sensors, as well as proximity sensors, image signal processors, single photon detectors, inclu

Pfizer NYSE:PFE

$25.56 -0.58 (-2.22%)

Closing price 03:58 PM Eastern

Extended Trading

$25.62 +0.05 (+0.22%)

As of 05:45 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Schrödinger NASDAQ:SDGR

$21.45 -1.30 (-5.71%)

Closing price 04:00 PM Eastern

Extended Trading

$21.58 +0.13 (+0.61%)

As of 05:41 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SDGR, AZN, AZN, AZNCF, LLY, GSK, GSK, ON, and PFE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SDGR, AZN, AZN, AZNCF, LLY, GSK, GSK, ON, and PFE Earnings

Compare Dividends

Latest SDGR, AZN, AZN, AZNCF, LLY, GSK, GSK, ON, and PFE Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SDGR, AZN, AZN, AZNCF, LLY, GSK, GSK, ON, and PFE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SDGR, AZN, AZN, AZNCF, LLY, GSK, GSK, ON, and PFE Company Descriptions

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools